Position of the Transparency Council – Reblozyl (luspatercept)
At its meeting on 24 March 2025, the Transparency Council adopted position No. 36/2025 on the evaluation of the drug Reblozyl (luspatercept) under the drug program: B.142. “Treatment of adult patients with myelodysplastic syndromes with transfusion-dependent anemia (ICD-10: D46.0, D46.1)”